Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could be ...

UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europe from France’s Institut ...

SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for ...

Behringer is no stranger to remaking classic synthesizers and selling them at much cheaper price points. However, this latest release may just take the budget-friendly cake. The company just ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

ABL Bio said on the 12th that it signed a technology transfer and joint research and development agreement with U.S.-based Eli Lilly for the "Grabody-B" platform, a technology that penetrates the ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...

ABL Bio announced on the 1st that it confirmed the safety and tolerability of the treatment candidate ABL301 (SAR446159) for degenerative brain diseases such as Parkinson's disease in a U.S. Phase 1 ...

Former small-satellite launch company ABL Space Systems has capped a transformation to focus on missile defense by changing its name, the CEO of newly rebranded Long Wall announced Feb. 19. "As our ...